Enrollment Begins for CIRSE Registry of SIR-Spheres to Treat Liver Cancer

January 19, 2015—The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has launched the CIRSE Registry for SIR‐Spheres Therapy (CIRT). This is a single‐device registry that was developed by the society in collaboration with Sirtex Medical Ltd., the manufacturer of SIR‐Spheres Y‐90 resin microspheres. SIR-Spheres microspheres are a medical device used in selective internal radiation therapy to treat liver tumors.

According to CIRSE, this Europe‐wide observational study on the treatment of primary and secondary liver tumors with SIR‐Spheres has been designed to collect a large amount of data on the real‐life application of selective internal radiation therapy, also known as radioembolization. The study will also collect extensive quality‐of‐life data to learn more about the palliative aspect of treatment with SIR‐Spheres microspheres. Previous research on this device has shown positive results in the treatment of liver cancer, noted CIRSE.

Professor José Ignacio Bilbao, MD, serves as Chairman of the CIRT steering committee. Professor Bilbao is Head of Interventional Radiology at Clínica Universidad de Navarra in Pamplona, Spain.

In the CIRSE announcement, Professor Bilbao commented, “CIRSE is pleased to have developed the CIRT registry, which we believe will help the doctors who administer SIR‐Spheres therapy to better understand the real‐life clinical application of SIR‐Spheres microspheres throughout Europe. Our goal is to enter treatment data on over 500 patients a year from more than 20 specialist European hospitals into the new CIRT registry.”